We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk to Acquire Dicerna for $3.3 Billion, Netting Platform for Targeting Disease-Causing Genes
Novo Nordisk to Acquire Dicerna for $3.3 Billion, Netting Platform for Targeting Disease-Causing Genes
Novo Nordisk plans to acquire Dicerna Pharmaceuticals for $3.3 billion, a move that will net Novo Nordisk a ribonucleic acid interference (RNAi) platform for identifying genes that can be targeted to develop drug candidates across many therapeutic areas.